Welcome to ActoGeniX

ActoGeniX is a biopharmaceutical company, focused on the development and commercialization of a new generation of biological drugs; ActoBiotics™.

About ActoGeniX

ActoGeniX’s mission is to develop and commercialize innovative biological therapies, to improve the treatment and well-being of patients with gastrointestinal, immunological and metabolic diseases.

 

More about ActoGeniX →

About ActoBiotics™

ActoBiotics™ represent a novel concept for oral administration of therapeutic proteins, and are designed to be safer and more effective than injectable biopharmaceuticals. This novel class of biopharmaceuticals has the potential to treat a broad range of severe diseases.

 

More about ActoBiotics™ →

Video: What are ActoBiotics™?

Watch our introduction video on ActoBiotiocs by clicking on the image.

 

Recent Updates

Please click here for the latest news and headlines from ActoGeniX.

Show all news & events

Belgium’s ActoGeniX to Join Intrexon

02/13/2015

Living Biofactories in Your Prescription Bottle? Belgium’s ActoGeniX to Join Intrexon Bringing New Generation of Orally Delivered Biotherapeutics   GERMANTOWN,.. read more

STALLERGENES AND ACTOGENIX TO DEVELOP AN INNOVATIVE NEW CLASS OF ORAL ALLERGY TREATMENTS

11/20/2014

STALLERGENES exercised option to pursue the exclusive development of application of ActoGeniX’s technology for targeted delivery of allergen-based treatments Antony,.. read more

Oral therapeutic proteins: a game changer for inflammatory and autoimmune disorders

10/30/2014

Nature | Biopharmadealmakers| November 2014 Oral therapeutic proteins: a game changer for inflammatory and autoimmune disorders This new class of.. read more